Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126683512 | 12668351 | 2 | F | 20120831 | 20160829 | 20160819 | 20160902 | EXP | NL-PFIZER INC-2015255903 | PFIZER | 65.00 | YR | M | Y | 73.00000 | KG | 20160902 | CN | NL | NL |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126683512 | 12668351 | 1 | PS | SOMAVERT | PEGVISOMANT | 1 | Subcutaneous | 40 MG, 1X/WEEK | 21106 | 40 | MG | POWDER AND SOLVENT FOR SOLUTION FOR INJECTION | /wk | ||||||
| 126683512 | 12668351 | 2 | SS | SOMAVERT | PEGVISOMANT | 1 | Subcutaneous | 40 MG, 1X/ WEEK | 21106 | 40 | MG | POWDER AND SOLVENT FOR SOLUTION FOR INJECTION | /wk | ||||||
| 126683512 | 12668351 | 3 | SS | SOMAVERT | PEGVISOMANT | 1 | Subcutaneous | 60 MG, 1X/WEEK | 21106 | 60 | MG | POWDER AND SOLVENT FOR SOLUTION FOR INJECTION | /wk | ||||||
| 126683512 | 12668351 | 4 | SS | SOMAVERT | PEGVISOMANT | 1 | Subcutaneous | 60 MG, 2X/WEEK | 21106 | 60 | MG | POWDER AND SOLVENT FOR SOLUTION FOR INJECTION | BIW | ||||||
| 126683512 | 12668351 | 5 | SS | SOMAVERT | PEGVISOMANT | 1 | Subcutaneous | 60 MG, 2X/WEEK | 21106 | 60 | MG | POWDER AND SOLVENT FOR SOLUTION FOR INJECTION | BIW | ||||||
| 126683512 | 12668351 | 6 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | 500 MG, 1X/DAY | 0 | 500 | MG | QD | ||||||||
| 126683512 | 12668351 | 7 | C | NOSCAPIN /00281701/ | 2 | 15 MG, UNK | 0 | 15 | MG | ||||||||||
| 126683512 | 12668351 | 8 | C | PANTOPRAZOL | PANTOPRAZOLE SODIUM | 1 | 40 MG, 1X/DAY | 0 | 40 | MG | QD | ||||||||
| 126683512 | 12668351 | 9 | C | LANREOTIDE | LANREOTIDE | 1 | 0.4 ML (300 MG/ML), UNK | 0 | .4 | ML | |||||||||
| 126683512 | 12668351 | 10 | C | TESTOSTERON /00103101/ | TESTOSTERONE | 1 | 20 MG/G, 1X/DAY | 0 | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126683512 | 12668351 | 1 | Acromegaly |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126683512 | 12668351 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126683512 | 12668351 | Bone disorder | |
| 126683512 | 12668351 | Fatigue | |
| 126683512 | 12668351 | Lung disorder | |
| 126683512 | 12668351 | Off label use |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126683512 | 12668351 | 1 | 20120831 | 0 | ||
| 126683512 | 12668351 | 2 | 20120906 | 20121227 | 0 | |
| 126683512 | 12668351 | 3 | 20121228 | 20130207 | 0 | |
| 126683512 | 12668351 | 4 | 20130208 | 0 | ||
| 126683512 | 12668351 | 5 | 20150522 | 0 |